Bind clinical workflows to valid prerequisites.
A study protocol does not capture every condition governing a specific action. Approvals, consent, study state, data integrity and responsible roles must align in context. The pharmaceutical domain organizes these prerequisites and records the state on which a protected approval was based.
Pharma & klinische Studien: sector controls in institutional context
This sector page now anchors its relevant control families in the actual institutional workflow rather than treating gates as a detached catalog. The purpose is to show what each control contributes, which data and dependencies it requires, and how a material block affects the final execution state.
SECTOR PROCESS · ARCHITECTURE OVERVIEW
From a domain finding to a permitted action
Assessment of a clinical-trial event differs from approval by the competent body and permission for the specific action.
01 · INPUT & CONTEXT
What action is proposed, by which actor, on which object and at what time?
02 · DOMAIN CHECK
Applicable rules and data sources determine the domain state; a gate finding remains an input.
03 · AUTHORITY & RIGHTS
Legal basis, competent authority, scope, time and dependencies must be valid for the specific action.
04 · EXECUTION & EVIDENCE
Only a valid execution right permits a protected action; evidence records determination and execution status separately.
ILLUSTRATIVE MODEL · Not a live receipt or universal legal clearance. A positive gate check alone does not grant an execution right.
SECTOR GATE FAMILIES
Applicable control domains
The gate names below map publicly documented controls to this sector. Actual availability for a tenant is determined separately by institutional onboarding and valid Execution Rights™.
- gateClinicalTrials
- gatePharmaMedical
This mapping is neither a legal clearance nor a guarantee that every control is active for every tenant.
One clinical action can depend on several independent states.
The sector surface does not collapse protocol, consent, safety, regulatory and product conditions into one score. Each state remains separately attributable and can become an authorization dependency where the defined action requires it.
Protocol State
Version, amendment, applicable procedural conditions and protocol-bound dependencies.
Consent & Subject State
Encoded conditions around consent status and other defined subject-bound prerequisites.
Safety State
Adverse-event and safety-reporting facts remain evidence-bearing states and must not be suppressed by an authorization path.
Regulatory State
Applicable approvals, authorisations, jurisdiction and time-bound regulatory conditions.
Product / Batch State
Where relevant, product, batch, release, serialisation or conformity conditions can enter as dependencies.
Time & Evidence
The resolved state is bound to the relevant point in time and to attributable evidence rather than a generic compliance label.
Determination first. Execution rights™ second.
Two sector gates. Different purposes.
Evidence can strengthen accountability. It does not create medical or regulatory authority.
CAN
- Deterministically evaluate encoded, source-bound conditions.
- Bind domain determinations to a defined transaction or clinical state.
- Surface missing or conflicting authorization dependencies.
CANNOT
- Create ethics, regulatory or medical authority.
- Replace investigators, ethics committees, regulators, QPs or other competent roles.
- Turn a gate result into execution permission by itself.
Execution rights™ in Pharma and clinical trials
Execution rights™ for pharma and clinical trials: connect protocol versions, approvals, consent and current evidence before protected actions.
A trial approval applies to a particular version. A changed version must not take effect solely on the basis of the earlier approval.
The difference: a dashboard displays information and a log records events. The additional control question is whether the specific action may take effect under current conditions at the integrated execution path. A positive checking result alone is insufficient. Effectiveness must be accepted for the actual target systems and execution paths.
Serverless Edition™ · Jurisdictions · All sectors · The architecture difference